Congressman Mike Doyle

Representing the 18 District of Pennsylvania

Doyle Votes to Lower Prescription Drug Prices

December 12, 2019
Press Release
House bill will grant Medicare new powers to negotiate directly with drug companies for lower prices

Washington, DC – December 12, 2019 – U.S. Representative Mike Doyle (PA-18), announced that he voted in favor of a bill to lower Americans’ prescription drug prices, which was approved by the House today on a vote of 230 to 192.

“I’ve been working to lower prescription drug prices for many years, so I’m very happy that we’ve finally been able to move this bill through the House,” Congressman Doyle said this afternoon. “This vote is a big win for consumers.”

“So many Americans say they have difficulty affording their prescription medicines,” Congressman Doyle observed. “In fact, nearly a third of all adults report not taking their medicines as prescribed at some point in the past year because they couldn’t afford to. That ought to be unacceptable to everyone. Americans often pay three, four, or even 10x more than people living in other developed countries – simply because our government does not negotiate for better prices.”

“I believe Americans ought to be paying less for their prescription drugs - especially since we are already contributing tax dollars to medical research that makes new drugs possible - and that American shouldn’t have to pay more for their medicines than the rest of the world,” Congressman Doyle added. “That’s why I’ve been working with other House Democrats on legislation to lower prescription drug prices, and why I voted for H.R. 3 today.”

 H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act would:

  • Give Medicare the power to negotiate directly with the drug companies for lower drug prices;
  • Make those lower drug prices available to Americans with private insurance, not just Medicare beneficiaries;
  • Prohibit drug companies from charging Americans significantly more than they charge other countries for the same drugs;
  • Create a new, $2,000 out-of-pocket limit on prescription drug costs for Medicare Part D enrollees;
  • Prohibit drug companies from increasing prices beyond inflation every year;
  • Use the savings from negotiating lower drug prices: 
  • for more research to find new breakthrough treatments and cures;
  • to expand Medicare coverage to include vision, hearing, and dental benefits; and 
  • to combat the opioid epidemic and provide funding to states most heavily impacted by the crisis.

###

Issues: